Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTIVE study of IMG-007 in adults with moderate-to-severe atopic dermatitis
2024-520117-50-00Phase 2Authorised
- Sponsor
- Inmagene Biopharmaceuticals
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing IMG-007 with Placebo (2 arms). Primary endpoint: Percent change from baseline in EASI at Week 24. Planned start Sep 2025; status: authorised.
02
Drugs
IMG-007
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-520117-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520117-50-00.